Y. Chu

发表

A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma

S. Perkins, I. Kirov, B. Shiramizu, 2021, Leukemia.

Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.

M. Cairo, J. Hochberg, J. Ayello, 2017, Experimental hematology.

Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease

Bryon D Johnson, J. Verbsky, M. Cairo, 2022, Frontiers in Immunology.

303 Targeting Ewing sarcoma with anti-IL1RAP chimeric antigen receptor modified natural killer cells

D. Dimitrov, Haifeng Zhang, M. Cairo, 2022, Regular and Young Investigator Award Abstracts.

Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors

M. Cairo, Gaurav Nayyar, Y. Chu, 2019, Front. Oncol..

Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma

P. Hanley, M. Cairo, M. Barth, 2016, British journal of haematology.

Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity.

E. Haddad, B. Moriarity, M. Cairo, 2020, Seminars in hematology.

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice

J. Safrit, P. Soon-Shiong, M. Cairo, 2021, Journal for ImmunoTherapy of Cancer.

Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice

Brian W Huang, M. Barth, Yaya Chu, 2017, Oncoimmunology.

Resistance to Bruton’s Tyrosine Kinase Signaling Pathway Targeted Therapies

M. Cairo, A. Beishuizen, Y. Chu, 2019, Resistance to Targeted Anti-Cancer Therapeutics.

Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory mature B

M. Cairo, L. Baxter‐Lowe, B. Mehta, 2022, Leukemia & lymphoma.

Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56Dim NK cells

M. Lim, M. Cairo, C. McGuinn, 2019, Innate immunity.

Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.

D. Teachey, M. Cairo, E. Lowe, 2023, Best practice & research. Clinical haematology.

Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model

S. Perkins, M. Lim, M. Hermiston, 2018, Oncoimmunology.

Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice

M. Czuczman, M. Cairo, J. Hochberg, 2014, Cancer Immunology Research.

Advances in cellular and humoral immunotherapy – implications for the treatment of poor risk childhood, adolescent, and young adult B‐cell non‐Hodgkin lymphoma

M. Cairo, A. Termuhlen, Yaya Chu, 2019, British journal of haematology.

Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.

M. Cairo, A. Saha, Yaya Chu, 2014, Cytotherapy.

881 Significant therapeutic effects of anti-ROR1 CAR NK against neuroblastoma by oncolytic virus armored with IL-21in-vitroandin-vivo

E. Mardis, G. Behbehani, S. Riddell, 2022, Regular and Young Investigator Award Abstracts.

Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL

C. Klein, M. Cairo, Dean Anthony Lee, 2020, Oncotarget.

The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)

M. Cairo, Dean Anthony Lee, Yaya Chu, 2022, Current Treatment Options in Oncology.

Novel cytokine–antibody fusion protein, N-820, to enhance the functions of ex vivo expanded natural killer cells against Burkitt lymphoma

J. Safrit, P. Soon-Shiong, M. Cairo, 2020, Journal for ImmunoTherapy of Cancer.

Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy.

M. Cairo, A. Flower, Y. Chu, 2016, Methods in molecular biology.

Feasibility, Safety and Efficacy of Haploidentical Viral Cytotoxic T-Lymphocytes for Children, Adolescents, and Young Adults (CAYA) with Refractory Viral Infections in Primary Immunodeficiencies (PID) Post Solid Organ Transplant (SOT) or Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT)

M. Cairo, Dean Anthony Lee, C. Dvorak, 2022, Transplantation and Cellular Therapy.

Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies

A. Ferrando, S. Perkins, M. Lim, 2012, Blood Cancer Journal.

ROR1-Specific Chimeric Antigen Receptor (CAR) NK Cell Immunotherapy for High Risk Neuroblastomas and Sarcomas

S. Riddell, M. Cairo, Dean Anthony Lee, 2017 .

Therapeutic Effects of ALT-803, an IL-15 Superagonist, in Combination with Anti-CD20 Chimeric Antigen Receptor Modified Expanded Natural Killer CELLS Against Pediatric Burkitt Lymphoma (BL)

H. Wong, M. Cairo, Dean Anthony Lee, 2015 .

Effectively Targeting Burkitt Lymphoma By Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer Cells Combined with a Histone Deacetylase Inhibitor, Romidepsin in Vitro and In Humanized NSG Mice

M. Cairo, J. Ayello, Ashlin Yahr, 2015 .

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

C. Klein, M. Cairo, Dean Anthony Lee, 2020, Blood.

Inflammation-mediated fibroblast activation and immune dysregulation in collagen VII-deficient skin

A. Izeta, Y. Liao, Olga Ibáñez-Solé, 2023, Frontiers in immunology.

Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice

Brian W Huang, M. Barth, J. Ayello, 2017, Oncoimmunology.

Adoptive cellular therapy after hematopoietic stem cell transplantation

C. Bollard, Pongthep Vittayawacharin, Y. Chu, 2024, American journal of hematology.